about
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancerSignal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their CrosstalksA cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactionsSwitching Roles of TGF-β in Cancer Development: Implications for Therapeutic Target and Biomarker StudiesTGFbeta in CancerDoxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse modelsSMAD proteins control DROSHA-mediated microRNA maturationCell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathwayConvergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells.Two faces of TGF-beta1 in breast cancer.Targeting the tumor microenvironment.TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progressionEpigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.PKCalpha-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-beta1.Perspectives on tissue interactions in development and disease.Novel clinical therapeutics targeting the epithelial to mesenchymal transitionTargeting Nodal in malignant melanoma cells.TGFβ-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential.Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.Strong impact of TGF-β1 gene polymorphisms on breast cancer risk in Indian women: a case-control and population-based study.A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.Novel and emerging targeted-based cancer therapy agents and methods.Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation.Partners in crime: the TGFβ and MAPK pathways in cancer progression.Biologic characteristics of premalignant breast disease.Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-β in breast cancer progressionTranscriptional networks inferred from molecular signatures of breast cancerTransforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.Targeting signal transduction in pancreatic cancer treatment.Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapyMedea SUMOylation restricts the signaling range of the Dpp morphogen in the Drosophila embryoFrom cancer immunosurveillance to cancer immunotherapy.Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapyTransforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1.Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.TGF-β1 polymorphisms -509 C>T and +915 G>C and risk of pancreatic cancer.Tumor-stromal interactions in lung cancer: novel candidate targets for therapeutic intervention.
P2860
Q24625197-5D38EE89-D2C7-4A05-B38D-781B2893C1ABQ26752554-829409AE-DAE7-43B7-92AD-662248800A75Q27653116-8199C22F-6A20-484A-9957-AF811E097295Q28079488-16D234E8-4A43-42F4-B9D3-64D2ED546B0EQ28288866-7E626025-60D2-4B1B-9B17-6D9AA4862687Q28473783-B1938256-7A1C-49C5-AAD7-2AFF104A3082Q28941771-AEB0816B-C9FC-4932-A2DF-CCFA92F7F027Q30480593-40C6B3DF-C80C-44F6-BFB3-5B27F6D0EA05Q33588236-762785BB-CFED-4B55-B35B-BB63F5290FD7Q33661529-4DC3E449-C3AA-40B4-BF26-822B0A3AA2F6Q33736691-26AA0F5C-18AC-4828-81E0-FDF860B36D8EQ33936542-D09AB654-AE0E-4466-A393-86DE7AD0F87FQ34028615-A02C0138-6BDF-48D2-81E8-AD9FF9809589Q34076809-8F2F493A-5493-4C78-A41E-4EBD6FB10961Q34330027-9F6E1096-5F54-492B-83D9-B31E308B8E16Q34345818-E2426B1F-8ACC-4AC7-BC9B-323C58D5A969Q34610503-5B9085AD-1538-432A-828B-F0E732EB54E8Q34616525-B8D7AEF6-38E6-4180-8764-E77B08113C89Q34616814-992FACA5-2D81-4E15-B28B-F7480804F93DQ34935319-CD6FCD3D-2853-4909-8927-063514073B10Q35022568-91B8D4B0-A989-4DB5-B520-CF6C90537853Q35194888-77D882F1-21EE-4B9F-B686-7262B37AAD4AQ35558057-CE93C48D-684F-4192-95DF-E96C8F7D11A6Q35579455-3554F046-7A4B-4DBE-A79E-A25FC9239561Q35744886-38DFFF7A-D017-4852-BC5C-6743507C6F90Q36204798-60BFFFF0-7A82-4B1A-8441-F55E8B8427DFQ36207817-FCC1CA1A-F6DF-4F4E-8787-83892108ECD5Q36559648-E4A768FC-E3D5-4654-A380-5B6B7A41D8F9Q36801053-427323CA-B0C8-4599-AB96-E0E67D635B55Q36804444-38094826-9C2B-4AB0-A9DE-BA9CA1672784Q36806950-3D704B7C-7748-417A-A0C2-22BDC426B944Q36898100-DD673272-15B0-436C-9499-A45BE61F9A3DQ36990588-CD280D49-1E7B-4F8B-AED0-90DA2BD3FDB4Q37087603-F5CA3D30-92F6-4645-A75E-62E3EFA6F043Q37118372-5739AF11-DD23-4476-AA83-900CD32184CFQ37219226-229755DF-3B36-4D1A-B58D-982E47B622B6Q37326107-8F73E312-18B6-4F19-830B-7368CAD7FB92Q37598949-F038198A-81A0-4B62-BC64-2B07651BC133Q37694978-93A0B4A3-A714-4457-A468-8D9981F8EE6BQ38016208-7A75DB97-838C-46E5-B033-A65F632763F5
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Inhibition of TGFbeta signaling in cancer therapy.
@ast
Inhibition of TGFbeta signaling in cancer therapy.
@en
type
label
Inhibition of TGFbeta signaling in cancer therapy.
@ast
Inhibition of TGFbeta signaling in cancer therapy.
@en
prefLabel
Inhibition of TGFbeta signaling in cancer therapy.
@ast
Inhibition of TGFbeta signaling in cancer therapy.
@en
P1476
Inhibition of TGFbeta signaling in cancer therapy.
@en
P2093
Carlos L Arteaga
P356
10.1016/J.GDE.2005.12.009
P577
2005-12-27T00:00:00Z